A Medicare GLP-1 bridge program marks 2026, while multi-agonists like CagriSema are poised to lead the next wave of obesity therapy.
Anne M. Komé, PharmD, CPP, BCACP, CDCES
Advertisement
Articles by Anne M. Komé, PharmD, CPP, BCACP, CDCES
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Heidi Overton's FDA Nomination Could Mean for Pharmacy
2
New Lipid Drugs and What Pharmacists Need to Know
3
Building the pharmacy of the future — trust, loyalty, and growth
4
Reading CKM Signals Together: A Pharmacist's Guide
5